Q2
MRK — Q2 2026 Financial Report Analysis
Merck grew Q2 2026 sales 5% to $16.6bn but reported a $1.3bn net loss, entirely because a $5.7bn non-deductible charge for the Terns Pharmaceuticals acquisition was expensed on the spot — while gross profit fell in absolute dollars despite the revenue growth.